ReviewSeminars in cancer biology2014
HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection.
Review in Seminars in cancer biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Molecular biomarkers associated with ATLL and HAM progression in HTLV-1 infection: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Pooled it
- An overview of sequencing technology platforms applied to HTLV-1 studies: a systematic review.Archives of virology · 2021Pooled it
- Low genetic diversity of the Human T-cell Lymphotropic Virus (HTLV-1) in an endemic area of the Brazilian Amazon basin.PloS one · 2018Trial
- Host genetic determinants of HTLV-1 infection outcomes.Immunologic research · 2026Review
- Immunological Determinants of Oncogenic Virus-Driven Cancers in Africa: Mechanisms, Co-Infections and Public Health Challenges.Pathogens (Basel, Switzerland) · 2026Review
- Review
- Cytotoxic Effects of a Triorganotin Derivative on HTLV-1-Infected Cells at Different Immortalization/Transformation Stages In Vitro.Molecules (Basel, Switzerland) · 2026Article
- Telomerase in cancer- ongoing quest and future discoveries.Molecular biology reports · 2025Review
- Investigating STLV-1 infection in African green monkeys: a model for understanding HTLV-1 pathogenesis.Frontiers in medicine · 2025Article
- Anti-HTLV-1 immunity combined with proviral load as predictive biomarkers for adult T-cell leukemia-lymphoma.Cancer science · 2024Article
- How molecular advances may improve the diagnosis and management of PTCL patients.Frontiers in oncology · 2023Review
- Article
- BET-Independent Murine Leukemia Virus Integration Is RetargetedMicrobiology spectrum · 2022Article
- Circulating Virus-Host Chimera DNAs in the Clinical Monitoring of Virus-Related Cancers.Cancers · 2022Review
- Updates on HTLV-1 Uveitis.Viruses · 2022Review
- NK cells and monocytes modulate primary HTLV-1 infection.PLoS pathogens · 2022Article
- Article
- Epigenetic Regulation of Human T-Cell Leukemia Virus Gene Expression.Microorganisms · 2021Review
- Immunoprofiling of fresh HAM/TSP blood samples shows altered innate cell responsiveness.PLoS neglected tropical diseases · 2021Article
- Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Human T lymphotropic virus type 1 (HTLV-1) causes a range of chronic inflammatory diseases and an aggressive malignancy of T lymphocytes known as adult T-cell leukaemia/lymphoma (ATLL). A cardinal feature of HTLV-1 infection is the presence of expanded clones of HTLV-1-infected T cells, which may persist for decades. A high viral burden (proviral load) is associated with both the inflammatory and malignant diseases caused by HTLV-1, and it has been believed that the oligoclonal expansion of infected cells predisposes to these diseases. However, it is not understood what regulates the clonality of HTLV-1 in vivo, that is, the number and abundance of HTLV-1-infected T cell clones. We review recent advances in the understanding of HTLV-1 infection and disease that have come from high-throughput quantification and analysis of HTLV-1 clonality in natural infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.